AGE-RELATED MACULAR DEGENERATION (AMD)
Clinical trials for AGE-RELATED MACULAR DEGENERATION (AMD) explained in plain language.
Never miss a new study
Get alerted when new AGE-RELATED MACULAR DEGENERATION (AMD) trials appear
Sign up with your email to follow new studies for AGE-RELATED MACULAR DEGENERATION (AMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Doctors track eye fluid to predict future need for AMD injections
Disease control Recruiting nowThis study is observing how patients with 'wet' age-related macular degeneration (AMD) respond in the first two months after starting treatment with Eylea 8mg injections. Researchers will use special eye scans to measure fluid changes in the retina and check if vision improves. T…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Race to slow blinding eye disease in major drug trial
Disease control Recruiting nowThis study is testing two investigational drugs, pozelimab and cemdisiran, to see if they can slow down the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent central vision loss. The trial will involve about 975 partici…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
Spin bikes may slow vision loss in veterans
Disease control Recruiting nowThis study is testing whether a 6-month online stationary bike program can help preserve vision and improve overall health in Veterans with age-related macular degeneration (AMD). Researchers will compare 70 Veterans doing spin cycling against a control group to see if exercise a…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Could a multiple sclerosis pill be the answer to slowing blindness?
Disease control Recruiting nowThis study is testing whether an oral medication called TECFIDERA® (dimethyl fumarate), already used for multiple sclerosis, can slow the progression of geographic atrophy. Geographic atrophy is a form of 'dry' age-related macular degeneration that causes gradual, irreversible vi…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Tiny eye telescope could restore central vision for AMD patients
Disease control Recruiting nowThis study is testing a small implant called the SING IMT™ that acts like a tiny telescope inside the eye. It's designed for people with advanced age-related macular degeneration who have already had cataract surgery. Researchers want to see if this device can safely improve cent…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: NA • Sponsor: VisionCare, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New eye injection aims to halt leading cause of blindness
Disease control Recruiting nowThis study is testing whether an experimental eye injection called ONL1204 can slow the progression of geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. Researchers will compare different doses and schedules of the injection …
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
AI vs. doctor: the race to save sight in routine checkups
Diagnosis Recruiting nowThis study is testing whether artificial intelligence (AI) software can help family doctors and geriatric specialists better screen for two common causes of vision loss: diabetic eye disease and age-related macular degeneration. About 4,300 adults with diabetes or over age 50 wil…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Diagnosis
Last updated Mar 16, 2026 15:26 UTC
-
New eye gel aims to take the sting out of Vision-Saving injections
Symptom relief Recruiting nowThis study is testing if a new numbing gel (chloroprocaine) works as well as the current standard method (eye drops plus a small injection) to reduce pain during eye injections for conditions like macular degeneration and diabetic eye disease. About 236 adults who regularly get t…
Matched conditions: AGE-RELATED MACULAR DEGENERATION (AMD)
Phase: PHASE4 • Sponsor: Harrow Inc • Aim: Symptom relief
Last updated Apr 02, 2026 14:57 UTC